The Future of the Generics Industry
•
0 likes•623 views
The document discusses the future of the generics industry and global spending on medicines. It notes that global spending on medicines will grow nearly $1.2 trillion by 2016, with generics contributing a greater share. Developed markets will see slower growth due to patent expiries and cost containment actions. Pharmerging markets' spending share will increase due to population and economic growth driving higher medicine use. Generics can help reduce costs and maintain access to affordable medicines in the short and long term by increasing efficiency and freeing up funds for new therapies. A long term strategy of expanding generic use can generate ongoing savings while maintaining patient access.
Report
Share
Report
Share
Download to read offline
Recommended
High Drug Costs
Americans pay significantly more for prescription drugs than people in other Western nations. In 2000, Americans paid 60% more on average for brand name drugs compared to seven other Western nations. By 2003, Americans paid 81% more on average. For many patented drugs in 2003, Americans paid 58-118% more than people in Switzerland, Britain, Germany, Canada, Sweden, France, and Italy. High drug costs in the US are driven by the pharmaceutical industry spending billions on marketing to doctors, creating influence over prescribing decisions and loyalty to brand name drugs. Marketing accounts for 30% of drug costs while research and development accounts for only 10-15%. Expensive new drugs are heavily marketed, including for off-label uses, driving up overall
Global Medicines Use in 2020: Outlook and Implications
Over the next five years, global health is expected to see innovations in research, technology-enabled transformations, and measurable improvements to health outcomes by 2020. The volume of medicines used globally will reach 4.5 trillion doses and spending will reach $1.4 trillion, with China, India, Brazil and Indonesia accounting for nearly half of increased usage. Innovation will drive transformation of disease treatments with 225 new substances launched and over 470 drugs available to treat orphan diseases.
Medicines Use and Spending Shifts: A Review of the Use of Medicines
Growth in spending on medicines was higher in 2014 than any year since 2001, and
exceeded forecast overall healthcare spending growth for the first time since 2011.
As 2014 was also a landmark year in the implementation of the Affordable Care Act,
understanding the specific drivers of medicine spending growth is important for decisionmakers
across the healthcare system.
In this report we bring together several perspectives on 2014: total system spending on
medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery
and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including
retail prescription co-pays; and transformations in disease treatment resulting from newly
approved medicines.
Oncologics Spending Reached $43.4 billion in 2014
Oncologics led all classes in spending in 2014 with $32.3Bn in spending, or $43.4Bn including supportive care treatments.
Increasing Numbers of Launches and Growth in Spending on Specialty Products i...
The specialty products share of the R&D pipeline has increased 9% in the past decade, driven by drugs targeting cancer, nervous system disorders, infectious diseases, diabetes and respiratory disorders.
Health Exchange: Access to medicines April 2010
The document discusses improving access to essential medicines and identifies several problems. It notes that two billion people lack access to essential medicines, and there is a large price variation for treatments between countries. Stockouts of essential medicines also occur when health facilities experience shortages. The document proposes several solutions, including greater use of generics, changing how innovation is rewarded, improving governance and transparency, and partnerships between different stakeholders.
Vital medicines
Access to essential medicines in developing countries is inadequate, with availability only one third in the public sector and two thirds in the private sector, where prices are much higher. Improving access requires stronger partnerships among governments, pharmaceutical companies, and civil society. National essential medicines lists guide procurement and supply of affordable, effective treatments for communicable and non-communicable diseases, but 19% of developing countries need to update their lists. Low availability of medicines in public sectors means patients must pay higher costs privately or go without treatment.
Transformations in Disease Treatment
More new medicines were launched in 2014 than in any year since 2001 and included 23 breakthrough therapies and orphan drugs.
Recommended
High Drug Costs
Americans pay significantly more for prescription drugs than people in other Western nations. In 2000, Americans paid 60% more on average for brand name drugs compared to seven other Western nations. By 2003, Americans paid 81% more on average. For many patented drugs in 2003, Americans paid 58-118% more than people in Switzerland, Britain, Germany, Canada, Sweden, France, and Italy. High drug costs in the US are driven by the pharmaceutical industry spending billions on marketing to doctors, creating influence over prescribing decisions and loyalty to brand name drugs. Marketing accounts for 30% of drug costs while research and development accounts for only 10-15%. Expensive new drugs are heavily marketed, including for off-label uses, driving up overall
Global Medicines Use in 2020: Outlook and Implications
Over the next five years, global health is expected to see innovations in research, technology-enabled transformations, and measurable improvements to health outcomes by 2020. The volume of medicines used globally will reach 4.5 trillion doses and spending will reach $1.4 trillion, with China, India, Brazil and Indonesia accounting for nearly half of increased usage. Innovation will drive transformation of disease treatments with 225 new substances launched and over 470 drugs available to treat orphan diseases.
Medicines Use and Spending Shifts: A Review of the Use of Medicines
Growth in spending on medicines was higher in 2014 than any year since 2001, and
exceeded forecast overall healthcare spending growth for the first time since 2011.
As 2014 was also a landmark year in the implementation of the Affordable Care Act,
understanding the specific drivers of medicine spending growth is important for decisionmakers
across the healthcare system.
In this report we bring together several perspectives on 2014: total system spending on
medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery
and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including
retail prescription co-pays; and transformations in disease treatment resulting from newly
approved medicines.
Oncologics Spending Reached $43.4 billion in 2014
Oncologics led all classes in spending in 2014 with $32.3Bn in spending, or $43.4Bn including supportive care treatments.
Increasing Numbers of Launches and Growth in Spending on Specialty Products i...
The specialty products share of the R&D pipeline has increased 9% in the past decade, driven by drugs targeting cancer, nervous system disorders, infectious diseases, diabetes and respiratory disorders.
Health Exchange: Access to medicines April 2010
The document discusses improving access to essential medicines and identifies several problems. It notes that two billion people lack access to essential medicines, and there is a large price variation for treatments between countries. Stockouts of essential medicines also occur when health facilities experience shortages. The document proposes several solutions, including greater use of generics, changing how innovation is rewarded, improving governance and transparency, and partnerships between different stakeholders.
Vital medicines
Access to essential medicines in developing countries is inadequate, with availability only one third in the public sector and two thirds in the private sector, where prices are much higher. Improving access requires stronger partnerships among governments, pharmaceutical companies, and civil society. National essential medicines lists guide procurement and supply of affordable, effective treatments for communicable and non-communicable diseases, but 19% of developing countries need to update their lists. Low availability of medicines in public sectors means patients must pay higher costs privately or go without treatment.
Transformations in Disease Treatment
More new medicines were launched in 2014 than in any year since 2001 and included 23 breakthrough therapies and orphan drugs.
Federal tobacco control
This document summarizes recent initiatives in tobacco control and prevention in the United States. It discusses major programs from the Centers for Disease Control and Prevention, U.S. Food and Drug Administration, and new national strategies. It outlines opportunities like forthcoming media campaigns and warnings, as well as threats like new tobacco products and funding cuts. It concludes that spending on comprehensive tobacco control programs provides large economic benefits that greatly outweigh costs.
Prescription Medicines Costs in Context October 2020
This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.
Prescription Medicines - Costs in Context - October 2018
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare costs, certain patients face rising out-of-pocket costs. It also outlines the significant costs and risks of developing new medicines, with the average drug taking over 10 years and $2.6 billion to develop. The document proposes reforms to help lower costs for patients while supporting continued research and development of new treatments.
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
The unprecedented $20.2Bn increase in spending on new brands contributed 6.1% points to overall 13.1% growth in 2014.
Iihi us use_of_meds_for_2013
The document summarizes a report on medicine use and shifting healthcare costs in the United States in 2013. Key findings include:
- Healthcare and medicine utilization increased in 2013 as patient office visits rebounded after years of decline, while emergency room visits slowed. Prescriptions per capita also rose slightly.
- Out-of-pocket costs for patients continue to rise due to higher deductibles and co-payments, though most prescriptions cost $10 or less. Variations exist between insurance types.
- 36 new drugs were launched in 2013, including treatments for cancer, hepatitis C, and other diseases, transforming care for many conditions.
Biopharma Sales Resilience through Economic Recession
The document analyzes how sales of branded drug classes were impacted during the 2008/2009 economic recession. It hypothesizes that drug classes treating severe or acute conditions effectively with few alternatives would be most resilient. The analysis found biopharma generally more resilient than healthcare, though sales faced pressure from rising uninsured/Medicaid populations and tighter payer management. Drug classes addressing less severe issues or with low-cost options required ensuring continued access.
Global Pharmaceutical Management
MBA Pharma management, current trends in pharmaceutical industry. MBA Lectures on pharma management. This PPT discusses the various aspects of Global pharmaceutical industry. The PPT is intended for teaching MBA Pharma student only. Nature of Market growth:
Mature market – stagnant one , Europe, US, Germany, Japan, 10 key PMC, 78.9% amounted to USD 529.5 billion.
Emerging markets - manufacturers key growth segments, “Pharmerging markets”, China, Brazil, Mexico, South Korea and India
Prescription Medicines Costs in Context November 2019
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending, patients often face high out-of-pocket costs. It outlines the significant costs and risks of drug research and development. The document also describes the role of generics in reducing costs over time and how rebates and discounts do not always lower costs for patients.
Prescription Medicines Costs in Context March 2022
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
Prescription Medicines Costs in Context April 2022
This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.
Webinar 3: Bringing Home the 5% Solution
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
Americans cutting back on drugs and doctor visits
Americans are cutting back on prescription drugs and doctor visits due to rising healthcare costs. Visits to doctors declined by 4.7% in 2011 while emergency room visits increased by 7.4%. Older Americans especially are using fewer prescription drugs that treat conditions like high blood pressure and osteoporosis in order to save money. In contrast, prescriptions for young adults aged 19-25 rose by 2% as more were able to stay on their parents' health insurance plans under the Affordable Care Act.
Ims global use_of_meds_report_2013
Total global spending on medicines will exceed $1.2 trillion in 2017, an increase of $205-235 billion from 2012. The key countries of the US, EU5, Japan, and China will account for 67% of global spending in 2017, contributing 59% of growth. The mix of spending will shift toward generics, rising from 27% to 36% of total spending by 2017. Current pharmaceutical research holds potential to transform disease treatment across many areas, such as new oral drugs for rheumatoid arthritis and advances in cancer treatment. However, more research is still needed for diseases that have a high global burden, such as malaria, in emerging markets.
Prescription Medicines Costs in Context January 2020
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending represents 14% of total healthcare spending and a small portion of Medicaid spending, it has enabled breakthrough treatments for chronic diseases. While brand drug prices grew by 0.3% in 2018 after rebates, spending on other healthcare services is projected to grow 5 times faster than prescription drug spending through the next decade. The document also outlines how generics have reduced costs significantly, providing $1.99 trillion in savings over 10 years, and how biosimilars are expected to reduce brand drug sales by $95 billion from 2019-2023 through increased competition.
Cdc get smart week resident presentation 2014
This document discusses antibiotic overuse and resistance. It notes that overuse of antibiotics can lead to adverse drug events, antibiotic resistance, and Clostridium difficile infections. It summarizes the 2013 CDC Threat Report on antibiotic resistance and lists several "superbugs" as major threats. The document advocates for antibiotic stewardship programs and lists seven ways healthcare providers can improve antibiotic prescribing practices to help address the growing crisis of antibiotic resistance.
Medicines outlook through_2016_report
Medicines outlook through_2016_report
source of info:
http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionCanadian Organization for Rare Disorders
July 22, 2021 : Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Engage with our Expert Panel in a Townhall style meeting to add your voice on these important issues in preparation for upcoming federal election.
Panelist
Alexandra Chambers (Novartis)
Peter Brenders (BeiGene)
Angela Genge (The Neuro)
Fred Horne (3Sixty Public Affairs)
Leanne Ward (CHEO)Prescription Medicines Costs in Context May 2020
This document discusses prescription drug costs and spending in the United States. It notes that while 56 new medicines were approved by the FDA in 2019, out-of-pocket costs for patients continue to rise. While overall spending on prescription drugs grew by just 2.5% in 2018, nearly half of brand drug spending goes to entities other than the manufacturers. The document also compares US drug costs and availability to other countries.
Prescription Medicines - Costs in Context - September 2018
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Pitch Your Pills - Environmental Issues associated with prescription drug dis...
Pitch Your Pills overview at Florida Department of Environmental Protection for METRA, May 8, 2013. Learn more at seminolepreventioncoalition.org/pitchyourpills Presentation addressed the environmental issues associated with prescription drug disposal and providing an overview of Pitch Your Pills as a model campaign to implement permanent prescription drug disposal boxes. Led by William Morgan
Medicines outlook through_2016_report
The Global Use of Medicines: Outlook Through 2016. Report by the IMS Institute for Healthcare Informatics.
source of info: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
IMS Global Pharma Outlook 2016
The document summarizes key projections about global spending on medicines from 2012 to 2016. It finds that global spending will reach nearly $1.2 trillion by 2016, with developed markets' share declining to 57% as pharmerging markets increase their share to 30% through population and economic growth. There will be an accelerated shift to generics and biosimilars, accounting for $4-6 billion, while off-invoice discounts and rebates are estimated to reach $180-190 billion in 2016, lowering estimated global spending. New medicines are expected to transform treatment for diseases like cancer and Alzheimer's, though some gaps in available treatments will remain.
More Related Content
What's hot
Federal tobacco control
This document summarizes recent initiatives in tobacco control and prevention in the United States. It discusses major programs from the Centers for Disease Control and Prevention, U.S. Food and Drug Administration, and new national strategies. It outlines opportunities like forthcoming media campaigns and warnings, as well as threats like new tobacco products and funding cuts. It concludes that spending on comprehensive tobacco control programs provides large economic benefits that greatly outweigh costs.
Prescription Medicines Costs in Context October 2020
This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.
Prescription Medicines - Costs in Context - October 2018
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare costs, certain patients face rising out-of-pocket costs. It also outlines the significant costs and risks of developing new medicines, with the average drug taking over 10 years and $2.6 billion to develop. The document proposes reforms to help lower costs for patients while supporting continued research and development of new treatments.
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
The unprecedented $20.2Bn increase in spending on new brands contributed 6.1% points to overall 13.1% growth in 2014.
Iihi us use_of_meds_for_2013
The document summarizes a report on medicine use and shifting healthcare costs in the United States in 2013. Key findings include:
- Healthcare and medicine utilization increased in 2013 as patient office visits rebounded after years of decline, while emergency room visits slowed. Prescriptions per capita also rose slightly.
- Out-of-pocket costs for patients continue to rise due to higher deductibles and co-payments, though most prescriptions cost $10 or less. Variations exist between insurance types.
- 36 new drugs were launched in 2013, including treatments for cancer, hepatitis C, and other diseases, transforming care for many conditions.
Biopharma Sales Resilience through Economic Recession
The document analyzes how sales of branded drug classes were impacted during the 2008/2009 economic recession. It hypothesizes that drug classes treating severe or acute conditions effectively with few alternatives would be most resilient. The analysis found biopharma generally more resilient than healthcare, though sales faced pressure from rising uninsured/Medicaid populations and tighter payer management. Drug classes addressing less severe issues or with low-cost options required ensuring continued access.
Global Pharmaceutical Management
MBA Pharma management, current trends in pharmaceutical industry. MBA Lectures on pharma management. This PPT discusses the various aspects of Global pharmaceutical industry. The PPT is intended for teaching MBA Pharma student only. Nature of Market growth:
Mature market – stagnant one , Europe, US, Germany, Japan, 10 key PMC, 78.9% amounted to USD 529.5 billion.
Emerging markets - manufacturers key growth segments, “Pharmerging markets”, China, Brazil, Mexico, South Korea and India
Prescription Medicines Costs in Context November 2019
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending, patients often face high out-of-pocket costs. It outlines the significant costs and risks of drug research and development. The document also describes the role of generics in reducing costs over time and how rebates and discounts do not always lower costs for patients.
Prescription Medicines Costs in Context March 2022
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
Prescription Medicines Costs in Context April 2022
This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.
Webinar 3: Bringing Home the 5% Solution
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
Americans cutting back on drugs and doctor visits
Americans are cutting back on prescription drugs and doctor visits due to rising healthcare costs. Visits to doctors declined by 4.7% in 2011 while emergency room visits increased by 7.4%. Older Americans especially are using fewer prescription drugs that treat conditions like high blood pressure and osteoporosis in order to save money. In contrast, prescriptions for young adults aged 19-25 rose by 2% as more were able to stay on their parents' health insurance plans under the Affordable Care Act.
Ims global use_of_meds_report_2013
Total global spending on medicines will exceed $1.2 trillion in 2017, an increase of $205-235 billion from 2012. The key countries of the US, EU5, Japan, and China will account for 67% of global spending in 2017, contributing 59% of growth. The mix of spending will shift toward generics, rising from 27% to 36% of total spending by 2017. Current pharmaceutical research holds potential to transform disease treatment across many areas, such as new oral drugs for rheumatoid arthritis and advances in cancer treatment. However, more research is still needed for diseases that have a high global burden, such as malaria, in emerging markets.
Prescription Medicines Costs in Context January 2020
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending represents 14% of total healthcare spending and a small portion of Medicaid spending, it has enabled breakthrough treatments for chronic diseases. While brand drug prices grew by 0.3% in 2018 after rebates, spending on other healthcare services is projected to grow 5 times faster than prescription drug spending through the next decade. The document also outlines how generics have reduced costs significantly, providing $1.99 trillion in savings over 10 years, and how biosimilars are expected to reduce brand drug sales by $95 billion from 2019-2023 through increased competition.
Cdc get smart week resident presentation 2014
This document discusses antibiotic overuse and resistance. It notes that overuse of antibiotics can lead to adverse drug events, antibiotic resistance, and Clostridium difficile infections. It summarizes the 2013 CDC Threat Report on antibiotic resistance and lists several "superbugs" as major threats. The document advocates for antibiotic stewardship programs and lists seven ways healthcare providers can improve antibiotic prescribing practices to help address the growing crisis of antibiotic resistance.
Medicines outlook through_2016_report
Medicines outlook through_2016_report
source of info:
http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal ElectionCanadian Organization for Rare Disorders
July 22, 2021 : Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Engage with our Expert Panel in a Townhall style meeting to add your voice on these important issues in preparation for upcoming federal election.
Panelist
Alexandra Chambers (Novartis)
Peter Brenders (BeiGene)
Angela Genge (The Neuro)
Fred Horne (3Sixty Public Affairs)
Leanne Ward (CHEO)Prescription Medicines Costs in Context May 2020
This document discusses prescription drug costs and spending in the United States. It notes that while 56 new medicines were approved by the FDA in 2019, out-of-pocket costs for patients continue to rise. While overall spending on prescription drugs grew by just 2.5% in 2018, nearly half of brand drug spending goes to entities other than the manufacturers. The document also compares US drug costs and availability to other countries.
Prescription Medicines - Costs in Context - September 2018
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Pitch Your Pills - Environmental Issues associated with prescription drug dis...
Pitch Your Pills overview at Florida Department of Environmental Protection for METRA, May 8, 2013. Learn more at seminolepreventioncoalition.org/pitchyourpills Presentation addressed the environmental issues associated with prescription drug disposal and providing an overview of Pitch Your Pills as a model campaign to implement permanent prescription drug disposal boxes. Led by William Morgan
What's hot (20)
Prescription Medicines Costs in Context October 2020
Prescription Medicines Costs in Context October 2020
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
Biopharma Sales Resilience through Economic Recession
Biopharma Sales Resilience through Economic Recession
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context November 2019
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context April 2022
Prescription Medicines Costs in Context January 2020
Prescription Medicines Costs in Context January 2020
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Summer Webinar 1: Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Prescription Medicines - Costs in Context - September 2018
Prescription Medicines - Costs in Context - September 2018
Pitch Your Pills - Environmental Issues associated with prescription drug dis...
Pitch Your Pills - Environmental Issues associated with prescription drug dis...
Similar to The Future of the Generics Industry
Medicines outlook through_2016_report
The Global Use of Medicines: Outlook Through 2016. Report by the IMS Institute for Healthcare Informatics.
source of info: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
IMS Global Pharma Outlook 2016
The document summarizes key projections about global spending on medicines from 2012 to 2016. It finds that global spending will reach nearly $1.2 trillion by 2016, with developed markets' share declining to 57% as pharmerging markets increase their share to 30% through population and economic growth. There will be an accelerated shift to generics and biosimilars, accounting for $4-6 billion, while off-invoice discounts and rebates are estimated to reach $180-190 billion in 2016, lowering estimated global spending. New medicines are expected to transform treatment for diseases like cancer and Alzheimer's, though some gaps in available treatments will remain.
Medicines outlook through 2016 report
The future level of global spending on medicines underscores the similar challenges of access and affordability which face those who
consume and pay for healthcare around the world.
In the developed markets, including the United States and Europe, the current economic downturn will amplify many of the long-term
concerns about aging populations afflicted with expensive chronic diseases and the desire by all healthcare stakeholders to control costs.
Across countries, similar policies are already being implemented to rein in spending on expensive therapies, increase the use of generics,
address pricing directly through price cuts or indirectly via discounts or rebates, and develop a market for biosimilars as a lower-cost
alternative to original biologics.
Alternatively, the fast growing pharmerging markets will be driven predominantly by economic gains and rising incomes. This rise in
incomes, particularly for the lowest earners, coupled with government commitments to support expanded access to basic healthcare services,
will make medicines more broadly available and affordable to millions of people.
Further, new therapies for a range of diseases affecting both developed and developing world populations are currently, or will soon become,
available transforming patient care. Despite this progress, however, significant gaps remain in the drug arsenal.
In this report we quantify these factors and examine the spending and usage of medicines globally through 2016. We intend this report to
provide a foundation for meaningful discussion about the value, cost and role of medicines in healthcare over the next five years. Our report
was developed as a public service without industry or government funding.
Michael Kleinrock
Director, Research Development
IMS Institute for Healthcare Informatics
Medicines outlook through_2016_report (1)
The document summarizes key findings from a report on global pharmaceutical spending through 2016. It finds that:
1) Global drug spending will reach nearly $1.2 trillion by 2016, with developed markets accounting for 57% and pharmerging markets reaching 30% of spending.
2) The top 20 therapy areas, including oncology, diabetes, and asthma/COPD, will account for 42% of total spending.
3) Significant differences in per capita spending will remain, with developed countries averaging $609 per person and pharmerging countries $91.
Opioid Epidemic - Causes, Impact and Future
In 2017, everyday, more than 130 people died in the US after overdosing on opioids. This document talks about America's worst drug crisis ever and shares how technology can play a role to cope up with this epidemic.
IMS - Global Use of Medicines 2020 by Nitesh Bhele
By 2020, global medicine use will reach 4.5 trillion doses, a 24% increase from 2015 levels. Over half of the world's population will consume over 1 dose per person per day, driven by increased access in large emerging markets like India, China, Brazil, and Indonesia. Developed markets will continue to use more branded and specialty medicines per capita, while emerging markets will see greater use of generics and over-the-counter drugs. New medicines introduced in the past 10 years will account for 0.1% of volumes in emerging markets versus 2-3% in developed markets.
Final
This document provides an overview of research methodology for studying the Indian pharmaceutical market and the effect of healthcare products. The objectives are to understand the market contribution of healthcare products and evaluate consumers' and doctors' attitudes towards these products. Secondary research will gather data from company sources, while primary research will involve interviews with chemists, doctors, and consumers. The study aims to benefit researchers, the sponsoring organization, and colleagues by providing insights into opportunities in the domestic pharmaceutical market.
Homeopathy Product Market - Higher Growth Rate & Forecast 2017 - 2025
The document summarizes a report on the global homeopathy product market between 2017 and 2025. It finds that the market is growing due to increasing demand for alternative medicines and rising healthcare spending. While homeopathy treatments are cost-effective and widely available in various forms like tablets and tinctures, there is an absence of quality control regulations that is negatively impacting the market. However, ongoing clinical studies are finding benefits of homeopathy for conditions like allergic rhinitis, demonstrating the market potential. Asia Pacific is expected to be a major market due to high population and demand for low-cost treatments. The key players in the market are Standard Homeopathic Company, Homeocan inc., and Boiron Group.
Pharmaceutical Supply Chain Dynamics and Intelligence
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
The New Pharma Ecosystem: 2014 Trends Reshaping the Pharmaceutical Supply Chain
The pharmaceutical industry is undergoing tremendous changes. Numerous forces are re-shaping the new pharmaceutical ecosystem. Technology, demographics, regulations and shifts in wealth are creating transformative change. Increasingly becoming a more patient-centric world, patients use Smart devices to monitor research and evaluate pharmaceutical products. Healthcare reform regulations, the devaluation of the existing pharma model and trend towards patient empowerment and access to information are shaping the changing pharma industry, much as the retail industry was shaped by the multichannel and omni channel retailing trends of recent years. Regulators have become increasingly more cautious when improving innovative medicines. As pharmaceuticals have become more successful in prolonging life and treating illness, many medical conditions are now chronic. Today healthcare providers have become increasingly interested in measuring the outcomes of pharma performance and basing pricing accordingly. There has been a dramatic increase in prescription volume and an increased production and use of generic drugs. Producing pharmaceuticals in other countries can be complicated. Customs, local regulations and other factors impact products and require brands to adapt. Generic pharmaceuticals are becoming the dominant category globally, especially in developing rather than just industrial countries. Adding to the complexity, a large number of pharmaceutical products are made by multiple countries. These factors and the move towards specialty pharmaceuticals and greater production of pharmaceutical products globally have resulted in more pressure on global supply chains. Because supply chains have moved from local to global in operation, even one significant event can interrupt the global supply chain. Events such as hurricanes and typhoons, earthquakes, political and economic upheaval can have serious impacts on global supply chains, adding unforeseen costs and delays. Health care reform magnifies the effect of longer supply chains and increases the intense cost pressure on drug manufacturers. In order to reduce costs, more production as well as research and development are being offshored and outsourced.
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
Remarks by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the National Association of Attorneys Generals’ April 2017 Summit.
For more on the event, please visit: https://cvshealth.com/thought-leadership/making-progress-how-public-and-private-stakeholders-are-collaborating-to-improve-care
Pharma 2020
The pharmaceutical supply chain will undergo three major changes over the next decade: 1) it will fragment with different models for different drug types and patient groups, 2) it will become a means of market differentiation and economic value, and 3) it will become bidirectional with information flowing upstream to drive downstream product and service flow. The global drug market is growing and shifting to different therapeutic areas, while developing countries are seeing rising rates of chronic diseases previously associated with developed nations, opening new emerging opportunities.
Pharmaceutical Industry Analytics
GetWell operates over 2,000 drug stores across 5 European countries. The project aims to build a predictive model to forecast 4 weeks of daily sales for 1,000 GetWell stores in Germany. This will help optimize staffing schedules and inventory levels. The model seeks to understand various influencing factors like promotions, holidays, and competition to generate consistent sales forecasts.
CORD 2022 Rare Disease Day Webinar
CORD 2022 Rare Disease Day Webinar
Panel
• Étienne Richer, Associate Scientific Director, CIHR Institute of Genetics
• Thierry Lacaze-Masmonteil, Maternal, Infant, Child, Youth Research Network
• Fred Little, Country Lead, Rare Disease Canada, Pfizer
• Sandra Anderson, Senior Vice President, Innomar Strategies
• Paul Wilton, Vice-Chair, CORD
• Michelle Mujoomdar, Director, Specialty Pharmaceuticals, Health Canada
Pharmacy drug adherence march2013
Pharmacy drug adherence is important for both healthcare providers and patients. Value-based treatment involves choosing a drug regimen that controls disease progression while improving quality of life through medication compliance. However, low patient adherence costs the pharmaceutical industry over $500 billion per year, driving up drug prices and competition from generics. A proposed analytics solution segments patient populations by adherence behavior, profiles disease progression retrospectively in each segment, and uses predictive analytics to alert pharmacists about non-compliance risks so they can better communicate with patients about negative health outcomes from low adherence. This could help modify patient behavior, save $290 billion annually, and help meet goals of the Affordable Care Act by making patients more active participants in their own care.
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky Bare Sky Marketing Healthcare Content Writing Services
DELOITTE: 2017 Global Health Sciences Outlook Report - A global perspective on the healthcare industry and its strategic sectors. Deloitte efficiently delivers an uncomplicated but in-depth look at worldwide healthcare. Rising demand and associated spending are being fueled by an aging population; the growing prevalence of chronic diseases and comorbidities; development of costly clinical innovations; increasing patient awareness, knowledge, and expectations; and continued economic uncertainty despite regional pockets of recovery are just a few of the key issues and trends impacting the global health care sector.
Connect with me at LinkedIn and Twitter, visit my healthcare website -an industry resource since 2004...
Twitter: @johngbaresky
LinkedIn: https://www.linkedin.com/in/johngbaresky
My website: www.healthcaremedicalpharmaceuticaldirectory.com
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Drug Discovery, Development and Commercialization
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
The World’s Health Care Crisis: From the Laboratory Bench to the Patient’s Be...
Ibis Sánchez-Serrano, founder and CEO of The Core Model Corp., a corporate strategy and policy think tank, talks about the role of pharma in the World’s Health Care Crisis at the New York Public Library on Aug. 29, 2013. He says the major problem is lack of access to better, safer and more affordable medicines. This issue is present not only in the United States and the developing world but also in countries with socialized health care systems. This illustrated talk will provide a comparative analysis of healthcare systems throughout the world and address major issues within biotechnology and pharmaceutical industries.
Mera medicare
Mera Medicare is a unique business model which has potential to revolutionize healthcare industry by changing the way customers and healthcare professionals interact with each other. Mera Medicare provides an effective-tail platform to both healthcare professionals and customers while solving their key challenges.
Global Diabetes Drugs Market
Renub Research has recently published a report named "Global Diabetes Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2030," providing a detailed industry analysis that consists of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent growth in the Global Diabetes Drugs Market.
Similar to The Future of the Generics Industry (20)
IMS - Global Use of Medicines 2020 by Nitesh Bhele
IMS - Global Use of Medicines 2020 by Nitesh Bhele
Homeopathy Product Market - Higher Growth Rate & Forecast 2017 - 2025
Homeopathy Product Market - Higher Growth Rate & Forecast 2017 - 2025
Pharmaceutical Supply Chain Dynamics and Intelligence
Pharmaceutical Supply Chain Dynamics and Intelligence
The New Pharma Ecosystem: 2014 Trends Reshaping the Pharmaceutical Supply Chain
The New Pharma Ecosystem: 2014 Trends Reshaping the Pharmaceutical Supply Chain
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky
DELOITTE: 2017 Global Health Sciences Outlook Report - - John G. Baresky
The World’s Health Care Crisis: From the Laboratory Bench to the Patient’s Be...
The World’s Health Care Crisis: From the Laboratory Bench to the Patient’s Be...
More from Christopher Watt
Pharma Integrates 2013 Keynote Speaker Trevor M Jones CBE
Keynote Speaker Trevor M Jones CBE and his keynote address to Pharma Integrates 2013.
Pharma Integrates is an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.
Exploring the ‘tougher’ side of integration - What part should regulators and...
Exploring the ‘tougher’ side of integration - What part should regulators and patients play?
A presentation facilitated by Hedley Rees of biotech Pharmaflow at Pharma Integrates 2013, an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.
Exclusive overview of 2013 UK Life Sciences Start-up Environment: The Fourth ...
This document summarizes key points from Dr. Glenn Crocker's keynote address on the 2013 UK Life Sciences start-up environment. It notes that while start-up activity and investment in the UK have been declining in recent years, there are signs that large pharmaceutical companies are increasingly focusing on and funding early-stage startups. However, structural challenges around a shortage of experienced investors and difficulties companies face in execution still remain barriers to growth. The talk calls for longer-term, strategic funding from corporations, universities and philanthropic sources to help startups in their early stages and break the cycle of cautious investing.
Pharma Integrates 2013 - Beyond Account Management
Beyond Account Management. Leveraging Pharma supply-base capabilities to co-create value in the broader Healthcare sector
A presentation at Pharma Integrates 2013, an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.
Pharma Integrates 2013 - Jo Pisani
Why aren’t we strategically transforming Pharma business relationships?
A presentation by Jo Pisani of PWC at Pharma Integrates 2013, an event for senior management in the pharmaceutical industry created and run by Life Sciences Index.
Life Sciences Index presents Andrew Cox from IIAPS at Pharma Integrates 2013
Identifying and Defending Critical Assets: Is Pharma Different from Other Industries?
A Presentation at Pharma Integrates 2013 by Andrew Cox of IIAPS.
Pharma Integrates is an event for Senior management in the pharmaceutical industry created and run by Life Sciences Index.
More from Christopher Watt (6)
Pharma Integrates 2013 Keynote Speaker Trevor M Jones CBE
Pharma Integrates 2013 Keynote Speaker Trevor M Jones CBE
Exploring the ‘tougher’ side of integration - What part should regulators and...
Exploring the ‘tougher’ side of integration - What part should regulators and...
Exclusive overview of 2013 UK Life Sciences Start-up Environment: The Fourth ...
Exclusive overview of 2013 UK Life Sciences Start-up Environment: The Fourth ...
Pharma Integrates 2013 - Beyond Account Management
Pharma Integrates 2013 - Beyond Account Management
Life Sciences Index presents Andrew Cox from IIAPS at Pharma Integrates 2013
Life Sciences Index presents Andrew Cox from IIAPS at Pharma Integrates 2013
Recently uploaded
2024-6-01-IMPACTSilver-Corp-Presentation.pdf
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
Best Forex Brokers Comparison in INDIA 2024
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
一比一原版(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证文凭如何办理
永久可查学历认证【微信：A575476】【(QMUE毕业证书)英国爱丁堡玛格丽特女王大学毕业证成绩单Offer】【微信：A575476】（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信：A575476】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信：A575476】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
→ 【关于价格问题（保证一手价格）
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
一比一原版新西兰奥塔哥大学毕业证（otago毕业证）如何办理
一模一样【微信：A575476】【新西兰奥塔哥大学毕业证（otago毕业证）成绩单Offer】【微信：A575476】（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信：A575476】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信：A575476】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
→ 【关于价格问题（保证一手价格）
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSSIndustrial Tech SW: Category Renewal and Creation
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
How to Buy an Engagement Ring.pcffbhfbfghfhptx
Dive into this presentation and learn about the ways in which you can buy an engagement ring. This guide will help you choose the perfect engagement rings for women.
Negotiation & Presentation Skills regarding steps in business communication, ...
Business Communication & presentation Skills, Negotiation Skills
How HR Search Helps in Company Success.pdf
HR search is critical to a company's success because it ensures the correct people are in place. HR search integrates workforce capabilities with company goals by painstakingly identifying, screening, and employing qualified candidates, supporting innovation, productivity, and growth. Efficient talent acquisition improves teamwork while encouraging collaboration. Also, it reduces turnover, saves money, and ensures consistency. Furthermore, HR search discovers and develops leadership potential, resulting in a strong pipeline of future leaders. Finally, this strategic approach to recruitment enables businesses to respond to market changes, beat competitors, and achieve long-term success.
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
9356872877Sattamatka.satta.matka.satta matka.kalyan weekly chart.kalyan chart.kalyan jodi chart.kalyan penal chart.kalyan today.kalyan open.fix satta.fix fix fix Satta matka nambar.Part 2 Deep Dive: Navigating the 2024 Slowdown
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
On episode 272 of the Digital and Social Media Sports Podcast, Neil chatted with Brian Fitzsimmons, Director of Licensing and Business Development for Barstool Sports.
What follows is a collection of snippets from the podcast. To hear the full interview and more, check out the podcast on all podcast platforms and at www.dsmsports.net
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka➒➌➎➏➑➐➋➑➐➐Dpboss Matka Guessing Satta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka Indian satta Matka Dpboss Matka Kalyan Chart Matka Boss otg matka Guessing Satta Digital Marketing with a Focus on Sustainability
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
Recently uploaded (20)
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
The Most Inspiring Entrepreneurs to Follow in 2024.pdf
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Registered-Establishment-List-in-Uttarakhand-pdf.pdf
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Satta Matka Dpboss Matka Guessing Kalyan Chart Indian Matka Kalyan panel Chart
Negotiation & Presentation Skills regarding steps in business communication, ...
Negotiation & Presentation Skills regarding steps in business communication, ...
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Indian Matka
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
Dpboss Matka Guessing Satta Matta Matka Kalyan Chart Satta Matka
The Future of the Generics Industry
- 1. 16.00 – 17.00 The Future of the Generics Industry Facilitated by: Luigi Martini Panellists Include: Ewan Livesey Alan Sheppard Kim Kjornas
- 2. Global Spending on Medicines Outlook to 2016 Global spending on medicines annually will grow to nearly $1.2 trillion by 2016, as the pharmerging markets, biologics and generics contribute a greater share of spending. Developed markets will suffer due to patent expiries, slower brand spending growth and increased cost containment actions by payers. Pharmerging markets share of spending will increase as population and economic growth will drive a dramatically higher use of medicines in these markets with a demand for affordable therapies. There will be an accelerated shift in spending to generics.
- 3. Where generics can help in the current environment Environment • Financial crisis and implica.ons • Growing Pa.ent expecta.ons Generic medicines Short term Cost reduc.on and access to affordable medicines Long term • Rapidly evolving technologies Increase efficiency and provide headroom for spend on new therapies Pressure on healthcare systems Socio economic factors • Ageing popula.on / chronic disease • Medical advancements • Specialty care / Biologics
- 4. The way ahead? Affordability of healthcare will remain a challenge for several years to come. Expenditure on medicines represents around 20% of the cost with expenditure on generic medicines being only 20% of this spend. As such generic medicines should be seen as a potential solution to the problem A longer term strategy of increasing usage of generics will generate ongoing savings and maintain access to medicines for patients Expanding the use of generic medicines allows for treatment of more patients within budgets without changing therapeutic approach Lowering prices threaten sustainability of the industry Fair margins within the supply chain can be a stabilizing factor